Behind the headlines: Could an immunotherapy treatment for the Epstein-Barr virus (EBV) treat MS?
Could a new immunotherapy treatment for EBV treat MS?
Research
Online research – can you help?
Can you spare 30 minutes to help with this research?
Online research – can you help? Read More »
New study provides strong evidence for role of Epstein Barr virus as a trigger for Multiple Sclerosis
Source MS Trust: New research has provided the strongest evidence yet that infection with the Epstein Barr virus (EBV) acts as a trigger for people to develop MS.
Temelimab: Early clinical trial suggests potential for remyelination
An update about the latest MS research
Temelimab: Early clinical trial suggests potential for remyelination Read More »
The team are recruiting 200 people with advanced progressive MS
Source MS Society: Last year, we announced a new trial testing if a drug called cladribine can slow down the worsening of arm and hand movement for people with advanced primary or secondary progressive MS.
The team are recruiting 200 people with advanced progressive MS Read More »
Participants wanted for research on the narratives of people with multiple sclerosis following a mindfulness programme.
Request from Abbie Turner, Trainee Clinical Psychologist, Exeter University
Machine learning identifies new subtypes of MS from MRI scans
Source MS Trust: Researchers wanted to find out if there are hidden patterns in MRI brain scans taken over time that would better identify biological differences in MS activity and detect progression earlier.
Machine learning identifies new subtypes of MS from MRI scans Read More »
Introducing Octopus – the world’s first multi-arm, multi-stage trial for MS
Source MS Society: We’re pleased to introduce Octopus – our revolutionary, multi-arm, multi-stage trial that will transform the way we test treatments for progressive MS.
Introducing Octopus – the world’s first multi-arm, multi-stage trial for MS Read More »
Ofatumumab licensed for active relapsing-remitting MS in UK
Source MS Society: The Medicines and Healthcare products Regulatory Agency (MHRA), and European Commission (EC) have licenced ofatumumab to treat adults with active relapsing MS.
Ofatumumab licensed for active relapsing-remitting MS in UK Read More »